ADMA Biologics (NASDAQ:ADMA) Director Buys $109,690.00 in Stock

ADMA Biologics Inc (NASDAQ:ADMA) Director Steve Elms acquired 7,000 shares of ADMA Biologics stock in a transaction dated Thursday, March 5th. The shares were bought at an average price of $15.67 per share, for a total transaction of $109,690.00. Following the transaction, the director owned 2,038,730 shares of the company’s stock, valued at approximately $31,946,899.10. The trade was a 0.34% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.

ADMA Biologics Price Performance

Shares of ADMA stock remained flat at $15.39 during mid-day trading on Monday. 658,964 shares of the stock traded hands, compared to its average volume of 2,737,747. The company has a debt-to-equity ratio of 0.16, a current ratio of 6.71 and a quick ratio of 3.74. The company has a 50-day simple moving average of $16.92 and a 200 day simple moving average of $16.77. ADMA Biologics Inc has a 1 year low of $13.76 and a 1 year high of $25.67. The stock has a market capitalization of $3.67 billion, a P/E ratio of 25.65 and a beta of 0.51.

ADMA Biologics (NASDAQ:ADMA) last posted its earnings results on Wednesday, February 25th. The biotechnology company reported $0.20 earnings per share for the quarter, meeting the consensus estimate of $0.20. The company had revenue of $139.16 million during the quarter, compared to analysts’ expectations of $139.80 million. ADMA Biologics had a net margin of 28.80% and a return on equity of 37.52%. ADMA Biologics’s quarterly revenue was up 18.4% on a year-over-year basis. During the same period last year, the company posted $0.46 earnings per share. On average, equities research analysts expect that ADMA Biologics Inc will post 0.51 earnings per share for the current year.

Institutional Trading of ADMA Biologics

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Salomon & Ludwin LLC purchased a new position in ADMA Biologics during the third quarter worth $25,000. Rothschild Investment LLC lifted its holdings in shares of ADMA Biologics by 373.8% in the 3rd quarter. Rothschild Investment LLC now owns 1,895 shares of the biotechnology company’s stock worth $28,000 after acquiring an additional 1,495 shares during the last quarter. Summit Securities Group LLC bought a new stake in shares of ADMA Biologics in the 4th quarter worth about $29,000. Clearstead Advisors LLC boosted its stake in shares of ADMA Biologics by 55.7% during the 3rd quarter. Clearstead Advisors LLC now owns 2,222 shares of the biotechnology company’s stock worth $33,000 after purchasing an additional 795 shares during the period. Finally, iSAM Funds UK Ltd bought a new position in ADMA Biologics during the 3rd quarter valued at about $34,000. Hedge funds and other institutional investors own 75.68% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on the company. Zacks Research raised ADMA Biologics from a “hold” rating to a “strong-buy” rating in a research note on Monday, March 2nd. Wall Street Zen raised ADMA Biologics from a “hold” rating to a “buy” rating in a report on Saturday, February 28th. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of ADMA Biologics in a research note on Tuesday, December 23rd. Two analysts have rated the stock with a Strong Buy rating and one has given a Hold rating to the company’s stock. Based on data from MarketBeat.com, ADMA Biologics has a consensus rating of “Buy” and an average target price of $32.00.

ADMA Biologics Company Profile

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company’s marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.